Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posoleucel - AlloVir

Next Previous
Drug Profile

Posoleucel - AlloVir

Alternative Names: ALVR-105; Multivirus-specific T cell therapy - AlloVir; Viralym-M

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer AlloVir; Baylor College of Medicine
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenovirus infections; Polyomavirus infections; Epstein-Barr virus infections; Cystitis; Cytomegalovirus infections; Human herpesvirus 6 infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adenovirus infections; Cystitis; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections

Most Recent Events

  • 01 Feb 2024 AlloVir terminates a phase III trial in Cystitis (In infants, In children, In adolescents, In adults, In the elderly) in the US, France, Italy, South Korea, Spain, UK and Sweden (IV, Infusion), since the DSMB determined it was futile. No safety concerns were noted (NCT04390113) (EudraCT2020-000722-26)
  • 31 Jan 2024 AlloVir terminates phase III trial in Human herpesvirus 6 infections, Epstein-Barr virus infections, Adenovirus infections, Cytomegalovirus infections, Polyomavirus infections (In adolescents, In adults, In children, In infants, In the elderly, Prevention) in the US, South Korea, France, Italy, Spain, in the UK, Australia, Belgium, Canada, Turkey due to no safety concerns were noted (NCT05305040)
  • 31 Jan 2024 AlloVir terminates the phase III trial in Adenovirus infections due to the DSMB's decision that it was futile and no safety concerns were identified (In infants, In children, In adolescents, In adults, In the elderly, Adjunctive treatment) in Canada, Italy, Spain, Sweden, United Kingdom, USA (IV) (NCT05179057)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top